On Tuesday Eli Lilly in an official statement announced the launch of Copellor in India. It is a drug indicated for moderate-to-severe plaque psoriasis in adults, who sometimes undergo phototherapy or systemic therapy. It will also be prescribed for active psoriatic arthritis adult patients.

It’s important to note that ‘psoriatic arthritis’ can develop due to psoriasis. Studies have shown that psoriasis enhances the risk of cardiovascular diseases, diabetes, inflammatory bowel diseases along with kidney diseases. No particular cause have been yet identified for psoriasis, but multiple factors such as environmental triggers, genetic makeup, etc might the cause diseases.

The Drug Controller General of India (DCGI) approved the drug, following which Eli Lily launched the drug. Copellor is a humanized IgG4 monoclonal antibody which specifically targets IL-17A protein, that is having a crucial role in triggering and sustaining inflammation in psoriasis.  Only a registered medical practitioner such as a dermatologist or rheumatologist can prescribe Copellor and is available in a single dose prefilled autoinjector with strength of 80 mg/ml.

(Source: https://www.financialexpress.com/healthcare/pharma-healthcare/eli-lilly-forays-into-the-dermatological-space-in-india-launches-psoriasis-drug/3008603/)